Zydus Lifesciences Ltd (ZYDUSLIFE)
Healthcare · Pharmaceuticals · NSE · Updated 1 October 2026
₹1,195.2↑ 21.75% (1Y)
🎯 Key Takeaways
- Revenue grew 5.7% QoQ to ₹8,017 in Q1FY27.
- Market Cap
- ₹1.19 L Cr
- P/E Ratio
- 26.6
- P/B Ratio
- 4.40
- ROE
- 16.6%
- ROCE
- 16.8%
- Debt/Equity
- 0.43
- Div Yield
- 0.08%
- Promoter
- 75.0%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 6,123 | 6,865 | 7,587 | 8,017 |
| Operating Profit | 1,714 | 1,457 | 2,046 | 1,375 |
| OPM % | 28.0% | 21.2% | 27.0% | 17.1% |
| Net Profit | 1,233 | 965 | 1,341 | 952 |
| EPS | ₹12.51 | ₹10.36 | ₹12.65 | ₹9.35 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 101 | 101 | 101 | 101 |
| Reserves | 23,853 | 21,724 | 27,011 | 25,201 |
| Borrowings | 3,213 | 191 | 11,770 | 9,636 |
| Total Liabilities | 37,202 | 31,446 | 52,407 | 46,897 |
| Fixed Assets | 6,042 | 6,102 | 26,639 | 7,099 |
| Investments | 6,408 | 2,596 | 7,540 | 5,878 |
| Total Assets | 37,202 | 31,446 | 52,407 | 46,897 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +2,117 |
| Investing | -8,296 |
| Financing | +5,807 |
| Net Cash Flow | -373 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 75.0% | 75.0% | 75.0% | 75.0% |
| FII | 7.3% | 7.1% | 7.0% | 6.9% |
| DII | 10.9% | 11.1% | 11.2% | 11.3% |
| Public | 5.5% | 5.5% | 5.5% | 5.5% |
| # Shareholders | 3,96,105 | 4,03,266 | 4,18,314 | 3,99,251 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Announcement2026-09-28Zydus Lifesciences announced that the USFDA closed its cGMP inspection of the Ahmedabad SEZ II plant on September 28, 2026, with one observation and n…
- 🔴 Announcement2026-09-26Zydus Lifesciences announced that the USFDA completed an inspection of its New Jersey pharmacovigilance and post-marketing surveillance system with no…
- Announcement2026-09-26Zydus Lifesciences has announced a trading window closure effective October 1, 2026, through October 3, 2026, following its upcoming unaudited financi…
- 🔴 Announcement2026-09-11Zydus Lifesciences announced it will attend the J.P. Morgan India Conference on September 21, 2026, as part of its ongoing investor engagement. The fi…
- 🔴 Announcement2026-09-11Zydus Lifesciences announced that CRISIL reaffirmed its long-term rating of CRISIL AAA/Stable and short-term rating of CRISIL A1+ for bank facilities,…
- Announcement2026-09-05Zydus Lifesciences disclosed that its U.S. subsidiary ZPUI settled indirect reseller claims in the Generic Pharmaceuticals Pricing Antitrust MDL by ag…
- 🟡 Board Meeting2026-09-01Zydus Lifesciences held its 31st AGM on August 11, 2026, virtually, with Chairman Pankaj R. Patel presiding. The meeting covered 9 agenda items includ…
- 🔴 Announcement2026-08-31Zydus Lifesciences announced positive topline results from its completed EVIDENCES-X Phase II(b) trial of Saroglitazar Magnesium for MASH, showing 26.…
- 🟡 related party transaction2026-08-26Zydus Lifesciences announced incorporation of wholly owned subsidiary Zydus Global Treasury Centre IFSC Limited in Gandhinagar, Gujarat, with Rs. 5 cr…
- 🔴 Insider Trading2026-08-24Zydus Lifesciences disclosed that Prashant Patel of the promoter group received 32,577 shares via transmission from his late mother Jasodaben Patel, a…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ZYDUSLIFE files new disclosures
Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ZYDUSLIFE — FreeFree account · 2 AI queries/day